Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17299753 | 0.85 | MAPKAPK2 (0.44) | MAPKAPK2KDM4AL3MBTL1STK17BSTK17A | |
| SCHEMBL18878472 | 0.84 | LMNA (0.51) | MAPKAPK2KDM4ALMNANFKB1BLM | |
| SCHEMBL24756661 | 0.76 | MAPKAPK2 (0.44) | MAPKAPK2KDM4AL3MBTL1STK17BSTK17A | |
| SCHEMBL23251840 | 0.75 | L3MBTL1 (0.45) | MAPKAPK2KDM4AL3MBTL1STK17BSTK17A | |
| SCHEMBL23795985 | 0.74 | KDM4A (0.42) | KDM4AL3MBTL1ATRLMNAKDM4E | |
| SCHEMBL30993280 | 0.73 | MAPKAPK2 (0.42) | MAPKAPK2KDM4AL3MBTL1ATRLMNA | |
| SCHEMBL13865274 | 0.72 | L3MBTL1 (0.44) | MAPKAPK2KDM4AL3MBTL1STK17BSTK17A | |
| SCHEMBL11927607 | 0.71 | MAPKAPK2 (0.57) | MAPKAPK2 | |
| SCHEMBL25097603 | 0.71 | L3MBTL1 (0.43) | MAPKAPK2KDM4AL3MBTL1STK17BSTK17A | |
| SCHEMBL21106557 | 0.71 | L3MBTL1 (0.43) | MAPKAPK2KDM4AL3MBTL1STK17BSTK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1889845-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SmithKline Beecham P.L.C. (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1538150-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2007-06-27 | — | — | EP | disclosed |
| EP-1538150-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-08 | — | — | EP | disclosed |
| EP-1351959-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-6900345-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-05-31 | — | — | US | disclosed |
| US-20040024059-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024059-A1 | Novel pleuromutilin derivatives | PLEC, MLNR, FABP2 | MAPKAPK2 1682/4885KDM4A 4686/4885L3MBTL1 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.